Beta Bionics Quarterly Income Statement
NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beta Bionics revenue and earnings
In the quarter ended Jun 30, 2026, Beta Bionics generated $32.0 million in revenue, up 37.8% from the same quarter a year earlier. Beta Bionics reported a net loss of $23.4 million, compared with a loss of $16.9 million a year earlier. Gross margin was 59.0% (up from 53.8%) and operating margin -79.9%.
Diluted earnings per share came in at -$0.53.
Summary generated from market data by MetaCap's automated system. Methodology
Beta Bionics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.01M | 27.63M | 32.12M | 27.25M | 23.24M | 17.64M | 20.44M | 16.70M | 15.05M | 12.93M |
| Revenue growth (YoY) | +37.76% | +56.62% | +57.15% | +63.14% | +54.45% | +36.39% | — | — | — | — |
| Cost of Revenue | 13.11M | 11.19M | 13.18M | 12.13M | 10.73M | 8.67M | 8.75M | 7.79M | 6.96M | 5.73M |
| Gross Profit | 18.90M | 16.44M | 18.94M | 15.12M | 12.50M | 8.97M | 11.69M | 8.91M | 8.08M | 7.20M |
| Operating Expenses | 44.48M | 40.71M | 35.07M | 32.16M | 32.38M | 27.61M | 24.73M | 19.89M | 19.87M | 16.65M |
| Research & Development | 10.24M | 10.36M | 10.13M | 8.20M | 8.87M | 7.59M | 9.21M | 5.14M | 6.35M | 5.48M |
| Selling, General & Admin | 34.24M | 30.35M | 24.94M | 23.97M | 23.50M | 20.02M | 15.51M | 14.75M | 13.52M | 11.18M |
| Operating Income | -25.58M | -24.27M | -16.12M | -17.04M | -19.87M | -18.64M | -13.04M | -10.98M | -11.78M | -9.45M |
| Other Income (Expense) | 2.17M | 2.38M | 2.66M | 2.83M | 3.00M | -10.01M | -5.07M | 1.24M | -2.68M | -3.00M |
| Net Income | -23.40M | -21.89M | -13.47M | -14.21M | -16.87M | -28.66M | -18.11M | -9.74M | -14.46M | -12.45M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.53 | -0.49 | -0.16 | -0.33 | -0.39 | -0.93 | -2.70 | -1.46 | -2.37 | -2.07 |
| EPS (Diluted) | -0.53 | -0.49 | -0.16 | -0.33 | -0.39 | -0.93 | -2.70 | -1.46 | -2.37 | -2.07 |
| Shares Outstanding (Basic) | 44.55M | 44.44M | — | 43.63M | 43.39M | 30.71M | — | 6.66M | 6.11M | 6.02M |
| Shares Outstanding (Diluted) | 44.55M | 44.44M | — | 43.63M | 43.39M | 30.71M | — | 6.66M | 6.11M | 6.02M |
| EBITDA | -24.87M | -23.69M | -15.59M | -16.66M | -19.52M | -18.34M | -12.80M | -10.64M | -11.48M | -9.17M |
| Gross Margin | 59.04% | 59.50% | 58.98% | 55.48% | 53.80% | 50.86% | 57.19% | 53.36% | 53.73% | 55.68% |
| Operating Margin | -79.90% | -87.86% | -50.20% | -62.54% | -85.52% | -105.69% | -63.78% | -65.71% | -78.32% | -73.09% |
| Net Margin | -73.10% | -79.26% | -41.92% | -52.14% | -72.59% | -162.46% | -88.59% | -58.28% | -96.13% | -96.26% |
This table shows 10 quarterly periods of Beta Bionics's income statement, from Q2 2026 back to Q1 2024, across 17 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BBNX's reporting calendar. What is a income statement?